Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
CRISPR diagnostics firm Sherlock Biosciences launches with $35 million
by Ryan Cross
March 29, 2019
| A version of this story appeared in
Volume 97, Issue 13
Sherlock Biosciences has raised $35 million to use CRISPR and synthetic biology approaches for rapid disease detection. The company is based on CRISPR technology developed in the lab of Feng Zhang at Broad Institute of MIT and Harvard and a paper-based DNA/RNA sensor developed in Jim Collins’s lab at the Wyss Institute at Harvard University. Sherlock’s nine cofounders include Zhang, Collins, and Pardis Sabeti, an infectious disease and Ebola expert at Harvard.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter